Dr. John Chute is a physician-scientist who studies hematopoietic stem cells (HSC, or blood stem cells) to develop therapies for diseases such as leukemia, by regenerating healthy blood cells to replace diseased cells. To accomplish this goal, his laboratory focuses on defining the mechanisms through which bone marrow cells regulate HSC self-renewal, repair and regeneration. Dr. Chute’s research has led to multiple discoveries including the function of ALDH1, a gene that is important in regulating HSC self-renewal, and the unique role of bone marrow endothelial cells, the cells that form the lining of blood vessels, in regulating HSC self-renewal and regeneration. During medical school and into his hematology-oncology fellowship, Dr. Chute became intrigued by the power of bone marrow stem cell transplantation to cure patients with otherwise incurable cancers. He was surprised by how little was understood about stem cell biology and embarked on a parallel scientific career to better understand blood stem cells. Dr. Chute is a member of the Broad Stem Cell Research Center and the Jonsson Comprehensive Cancer Center and is a Professor of Medicine in the Divisions of Hematology-Oncology and Radiation Oncology. He came to UCLA in 2014 from Duke University. Dr. Chute is a member of the American Society of Hematology, the American Society for Blood and Marrow Transplantation and serves as a regular member of the NIH Molecular and Cellular Hematology study section. He graduated summa cum laude and Phi Beta Kappa from the University of Notre Dame, was Valedictorian of his medical school class at Georgetown University, and has received the Young Investigator award from the American College of Physicians and the American Society of Clinical Oncology. He serves as an Associate Editor for Leukemia and the Journal of Clinical Investigation. Dr. Chute was elected to the American Society for Clinical Investigation in 2010. Dr. Chute’s research is funded by the National Institute for Allergy and Infectious Disease, the National Heart Lung Blood Institute and the Biomedical Advanced Research and Development Authority of H.H.S.